EP1178828A4 - Death domain containing receptor 4 - Google Patents

Death domain containing receptor 4

Info

Publication number
EP1178828A4
EP1178828A4 EP00932061A EP00932061A EP1178828A4 EP 1178828 A4 EP1178828 A4 EP 1178828A4 EP 00932061 A EP00932061 A EP 00932061A EP 00932061 A EP00932061 A EP 00932061A EP 1178828 A4 EP1178828 A4 EP 1178828A4
Authority
EP
European Patent Office
Prior art keywords
domain containing
death domain
containing receptor
methods
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00932061A
Other languages
German (de)
French (fr)
Other versions
EP1178828A1 (en
Inventor
Jian Ni
Craig A Rosen
James G Pan
Reiner L Gentz
Vishva M Dixit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
University of Michigan
Original Assignee
Human Genome Sciences Inc
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, University of Michigan filed Critical Human Genome Sciences Inc
Publication of EP1178828A1 publication Critical patent/EP1178828A1/en
Publication of EP1178828A4 publication Critical patent/EP1178828A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Abstract

The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides.
EP00932061A 1999-05-06 2000-05-05 Death domain containing receptor 4 Withdrawn EP1178828A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13292299P 1999-05-06 1999-05-06
US132922P 1999-05-06
PCT/US2000/012163 WO2000067793A1 (en) 1999-05-06 2000-05-05 Death domain containing receptor 4

Publications (2)

Publication Number Publication Date
EP1178828A1 EP1178828A1 (en) 2002-02-13
EP1178828A4 true EP1178828A4 (en) 2004-10-13

Family

ID=22456184

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00932061A Withdrawn EP1178828A4 (en) 1999-05-06 2000-05-05 Death domain containing receptor 4

Country Status (5)

Country Link
EP (1) EP1178828A4 (en)
JP (1) JP2002544172A (en)
AU (1) AU4984300A (en)
CA (1) CA2373063A1 (en)
WO (1) WO2000067793A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455040B1 (en) 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
DK1012274T4 (en) 1997-01-28 2011-07-25 Human Genome Sciences Inc Death domain-containing receptor-4 (DR4: death receptor 4), a member of the TNF receptor superfamily and which binds to TRAIL (Apo-2L)
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
WO2002094880A1 (en) * 2001-05-18 2002-11-28 Kirin Beer Kabushiki Kaisha Anti-trail-r antibodies
CN100594935C (en) 2001-05-25 2010-03-24 人体基因组科学有限公司 Antibodies that immunospecifically bind to trail receptors
WO2003013584A1 (en) * 2001-08-09 2003-02-20 Genset S.A. Xafinix agonists and antagonists for use in the treatment of metabolic disorders
ES2357225T3 (en) * 2001-11-01 2011-04-20 Uab Research Foundation COMBINATIONS OF ANTI-DR5 ANTIBODIES AND ANTI-DR4 ANTIBODIES AND OTHER THERAPEUTIC AGENTS.
WO2006067210A1 (en) * 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
US8129124B2 (en) 2005-02-02 2012-03-06 The Uab Research Foundation Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
US20160067337A1 (en) 2013-03-14 2016-03-10 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032856A1 (en) * 1997-01-28 1998-07-30 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
WO1999002653A1 (en) * 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
WO1999037684A1 (en) * 1998-01-26 1999-07-29 Genentech, Inc. Antibodies to death receptor 4 (dr4) and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032856A1 (en) * 1997-01-28 1998-07-30 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
WO1999002653A1 (en) * 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
WO1999037684A1 (en) * 1998-01-26 1999-07-29 Genentech, Inc. Antibodies to death receptor 4 (dr4) and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHANTRY D: "Tumour necrosis factor antagonists", EMERGING DRUGS 1999 UNITED KINGDOM, vol. 4, 1999, pages 5 - 13, XP008033630, ISSN: 1361-9195 *
DELGADO C ET AL: "RESEARCH ARTICLE. QUANTITATIVE ANALYSIS OF POLYETHYLENE GLYCOL (PEG) IN PEG-MODIFIED PROTEINS/CYTOKINES BY AQUEOUS TWO-PHASE SYSTEMS", JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, AMSTERDAM, NL, vol. 29, 1994, pages 237 - 250, XP000974417, ISSN: 0165-022X *
KIM K H ET AL: "Molecular determinants of response to TRAIL combined with chemotherapy in killing of normal and cancer cells", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03-01), & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999, pages 486, XP008033656, ISSN: 0197-016X *
MARSTERS S A ET AL: "Control of apoptosis signaling by Apo2 ligand.", RECENT PROGRESS IN HORMONE RESEARCH. 1999, vol. 54, 1999, pages 225 - 234, XP008033658, ISSN: 0079-9963 *
See also references of WO0067793A1 *

Also Published As

Publication number Publication date
WO2000067793A9 (en) 2002-04-18
CA2373063A1 (en) 2000-11-16
AU4984300A (en) 2000-11-21
WO2000067793A1 (en) 2000-11-16
WO2000067793A8 (en) 2001-05-25
JP2002544172A (en) 2002-12-24
EP1178828A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
CA2285040A1 (en) Death domain containing receptor 5
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO1998030693A3 (en) Tumor necrosis factor receptor 5
EP1003767A4 (en) Human tumor necrosis factor receptor tr10
WO1998031806A3 (en) Fc receptors and polypeptides
WO1998031818A3 (en) Tace-like and matrilysin-like polypeptides
AU9482498A (en) Interleukin-17 receptor-like protein
WO2001055310A8 (en) Nucleic acids, proteins, and antibodies
WO2001054472A3 (en) Nucleic acids, proteins, and antibodies
WO2000066156A8 (en) Death domain containing receptor 5
WO1999035262A3 (en) Apoptosis inducing molecule ii
WO2000067793A8 (en) Death domain containing receptor 4
WO2000054651A3 (en) Human tumor necrosis factor receptor-like genes
WO1998027932A3 (en) Cerebellum and embryo specific protein
EP1187842A4 (en) Human tumor necrosis factor receptor tr10
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
WO1998025957A3 (en) Human prt1-like subunit protein (hprt1) and human eif4g-like protein (p97) genes
WO2001005834A9 (en) Human tumor necrosis factor receptors tr13 and tr14
WO2002018622A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO2002057421A3 (en) Human tumor necrosis factor receptors tr13 and tr14
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
EP1712631A3 (en) Fc receptors and polypeptides
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040830

17Q First examination report despatched

Effective date: 20050614

17Q First examination report despatched

Effective date: 20050614

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20100906